We are live on ! Find out more
TRCT

Tower Research Capital (TRC) Portfolio holdings

AUM $4.08B
1-Year Est. Return 58.77%
This Fund
S&P 500
This Quarter Est. Return
+7.58%
1 Year Est. Return
+58.77%
3 Year Est. Return
+143.94%
5 Year Est. Return
+167.17%
10 Year Est. Return
+536.06%
AUM
$2.41B
AUM Growth
-$3.75B
Cap. Flow
-$4.09B
Cap. Flow %
-169.35%
Top 10 Hldgs %
31.78%
Holding
6,989
New
537
Increased
1,703
Reduced
3,620
Closed
686

Sector Composition

Rank Sector Weight
1 Technology 21.71%
2 Healthcare 7.7%
3 Consumer Discretionary 6.83%
4 Financials 6.52%
5 Industrials 4.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
DH icon
2251
Definitive Healthcare
DH
$68.4M
$57K ﹤0.01%
5,134
-576
-10% -$7.41K
FFBC icon
2252
First Financial Bancorp
FFBC
$3.6B
$57K ﹤0.01%
2,360
-14,212
-86% -$349K
GOCO
2253
DELISTED
GoHealth
GOCO
$57K ﹤0.01%
5,456
+5,449
+77,843% +$48.4K
IEV icon
2254
iShares Europe ETF
IEV
$1.7B
$57K ﹤0.01%
1,272
+1,087
+588% +$46.8K
JWN
2255
DELISTED
Nordstrom
JWN
$57K ﹤0.01%
3,524
-45,058
-93% -$862K
MBC icon
2256
MasterBrand
MBC
$1.89B
$57K ﹤0.01%
+7,547
New +$61.8K
PRPH
2257
DELISTED
ProPhase Labs
PRPH
$57K ﹤0.01%
+593
New +$64.1K
SDGR icon
2258
Schrodinger
SDGR
$1.38B
$57K ﹤0.01%
3,046
-3,326
-52% -$68.9K
SPRO icon
2259
Spero Therapeutics
SPRO
$71.8M
$57K ﹤0.01%
33,164
+14,925
+82% +$27.9K
TERN
2260
DELISTED
Terns Pharmaceuticals
TERN
$57K ﹤0.01%
5,539
-1,062
-16% -$7.07K
TFIN icon
2261
Triumph Financial Inc
TFIN
$1.87B
$57K ﹤0.01%
1,166
-10,368
-90% -$560K
VVX icon
2262
V2X
VVX
$2.55B
$57K ﹤0.01%
1,368
+766
+127% +$30.4K
RVNC
2263
DELISTED
Revance Therapeutics, Inc.
RVNC
$57K ﹤0.01%
3,083
-2,131
-41% -$48.7K
OMIC
2264
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$57K ﹤0.01%
937
+786
+521% +$52.7K
ASIX icon
2265
AdvanSix
ASIX
$446M
$56K ﹤0.01%
1,472
-641
-30% -$24K
CLLS
2266
Cellectis
CLLS
$320M
$56K ﹤0.01%
26,362
+19,300
+273% +$43.7K
CVNA icon
2267
Carvana
CVNA
$81B
$56K ﹤0.01%
58,575
-184,165
-76% -$389K
MED icon
2268
Medifast
MED
$128M
$56K ﹤0.01%
481
-388
-45% -$45.2K
MLNK
2269
DELISTED
MeridianLink
MLNK
$56K ﹤0.01%
4,073
+1,772
+77% +$27.3K
QCRH icon
2270
QCR Holdings
QCRH
$1.75B
$56K ﹤0.01%
1,139
-1,862
-62% -$95.9K
SMSI icon
2271
Smith Micro Software
SMSI
$16.2M
$56K ﹤0.01%
672
+275
+69% +$24K
QVCGA
2272
DELISTED
QVC Group Inc Series A
QVCGA
$56K ﹤0.01%
691
-77
-10% -$7.85K
SWAR
2273
DELISTED
Direxion Daily Software Bull 2X Shares
SWAR
$56K ﹤0.01%
+6,652
New +$59.2K
ATOM icon
2274
Atomera
ATOM
$212M
$55K ﹤0.01%
8,771
+5,437
+163% +$44.6K
BIRD icon
2275
Smartbird Inc
BIRD
$31.2M
$55K ﹤0.01%
1,150
+569
+98% +$33.3K

Similar funds

Tower Research Capital (TRC)'s Q4 2022 Portfolio in Review

As of Q4 2022, Tower Research Capital (TRC) held 6,989 positions worth $2.41B, down 61% from $6.16B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Tower Research Capital (TRC) withdrew a net $4.09B in Q4 2022, closing 686 positions and reducing 3,620 holdings. Its most notable exit was Vanguard Russell 2000 Value ETF, an estimated $4.46M position sold in full.

By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Tower Research Capital (TRC) opened a new position in iShares Semiconductor ETF worth $9.33M.

  • Tower Research Capital (TRC)'s largest Q4 2022 buy was iShares Semiconductor ETF: 80,454 shares worth $9.33M.
  • Tower Research Capital (TRC) added most to iShares Russell 2000 ETF in Q4 2022, an estimated $145M increase.
  • Tower Research Capital (TRC)'s biggest Q4 2022 reduction was Apple, cutting an estimated $322M.
  • Tower Research Capital (TRC) fully exited Vanguard Russell 2000 Value ETF in Q4 2022, selling an estimated $4.46M.
  • Tower Research Capital (TRC)'s ten largest holdings make up 32% of its $2.41B portfolio in Q4 2022.
  • Tower Research Capital (TRC) opened 537 new positions and closed 686 in Q4 2022.
  • Tower Research Capital (TRC)'s portfolio value fell 61% quarter-over-quarter to $2.41B.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2022, filed 10 Feb 2023.